An eIF4E-interacting peptide induces cell death in cancer cell lines

Area of Science:

• Molecular Biology
• Cell Biology
• Oncology

Background:

• Eukaryotic initiation factor 4E (eIF4E) is crucial for cap-dependent translation initiation in eukaryotes.
• Dysregulation of eIF4E is linked to oncogenic transformation and cancer development.
• Identifying novel therapeutic targets for cancer is a significant unmet need.

Purpose of the Study:

• To develop and evaluate a novel synthetic peptide targeting eIF4E for cancer therapy.
• To investigate the mechanism of cell death induced by the eIF4E-binding peptide.
• To assess the potential of this peptide as a pharmacophore for new cancer treatments.

Main Methods:

• Development of an eIF4E-binding peptide derived from Angel1, fused to a penetratin motif.
• Treatment of various epithelial cancer cell lines with the synthetic peptide.
• Analysis of cell death mechanisms, including ATP levels, F-actin network integrity, plasma membrane blebbing, and permeabilization.

Main Results:

• The synthetic eIF4E-binding peptide induced rapid and drastic cell death in multiple epithelial cancer cell lines.
• The observed cell death was necrotic, characterized by decreased ATP levels and F-actin network injury.
• Key events included extensive plasma membrane blebbing and increased membrane permeabilization.

Conclusions:

• A synthetic eIF4E-binding peptide derived from Angel1 demonstrates potent anti-cancer activity.
• The peptide induces necrotic cell death through disruption of cellular energy and cytoskeletal integrity.
• This peptide represents a promising candidate pharmacophore for developing novel cancer therapeutics.